Stockscreener 앱 받기
26.81
0.19%
-0.05
Rapport Therapeutics Inc 주식(RAPP)의 최신 뉴스
Discipline and Rules-Based Execution in RAPP Response - Stock Traders Daily
Breakout Zone: Is Rapport Therapeutics Inc gaining market shareWeekly Stock Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: A Biotech With 94.53% Potential Upside - DirectorsTalk Interviews
A Look At Rapport Therapeutics (RAPP) Valuation After FDA Clears Phase 3 Trial For RAP-219 - Sahm
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6.9%Time to Sell? - MarketBeat
FDA Phase 3 Green Light for RAP-219 Might Change The Case For Investing In Rapport Therapeutics (RAPP) - Sahm
Will Rapport Therapeutics Inc. stock outperform growth indexesJuly 2025 Sector Moves & Safe Capital Growth Tips - Улправда
Rapport Therapeutics, Inc. (RAPP): Investor Outlook with a Promising 84.56% Potential Upside - DirectorsTalk Interviews
Is Rapport Therapeutics Inc. stock a smart buy before Fed meeting2025 Sector Review & Free Expert Approved Momentum Trade Ideas - ulpravda.ru
Can Rapport Therapeutics Inc. stock resist market sell offsQuarterly Portfolio Review & Risk Managed Investment Entry Signals - ulpravda.ru
Form 8-KCurrent report - ADVFN
Rapport Therapeutics (RAPP) Refocuses Neurology Pipeline After RAP-219 Phase 3 Greenlight – What’s the R&D Tradeoff? - Yahoo Finance
A Quick Look at Today's Ratings for Rapport Therapeutics(RAPP.US), With a Forecast Between $40 to $56 - 富途牛牛
Rapport Therapeutics: Accelerated RAP-219 Epilepsy Path to Phase 3 and Strategic Pipeline Refocus Support Buy Rating - TipRanks
Rapport Therapeutics: Diversified Neurology Pipeline and Accelerated RAP-219 Development Underpin Buy Rating - TipRanks
Citizens reiterates Market Outperform rating on Rapport Therapeutics stock By Investing.com - Investing.com Canada
Rapport Therapeutics (RAPP) Receives FDA Clearance to Advance RAP-219 into Phase 3 Trials - Intellectia AI
Rapport To Advance Phase 3 Program Of RAP-219 In Focal Onset Seizures In Q2 - Nasdaq
Los Angeles Daily NewsRapport Therapeutics, Inc.Common Stock (Nasdaq:RAPP) Stock Quote - FinancialContent
Assessing Rapport Therapeutics (RAPP) Valuation After Recent Share Price Strength - Yahoo Finance
Rapport Therapeutics, Inc.Common Stock (NQ: RAPP - FinancialContent
Upcoming EventsRapport Therapeutics, Inc.Common Stock (Nasdaq:RAPP) Stock Quote - FinancialContent
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 7.8%Here's Why - MarketBeat
Have Rapport Therapeutics Insiders Been Selling Stock? - simplywall.st
Form 424B5 Rapport Therapeutics, - StreetInsider
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Program - TradingView — Track All Markets
Rapport Therapeutics Advances RAP-219 into Phase 3 Trials for Focal Onset Seizures, Expands Epilepsy Portfolio with New Program - Quiver Quantitative
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline - GlobeNewswire
What technical charts say about Rapport Therapeutics Inc. stock2026 world cup usa national team qualification goalkeepers possession football odds analysis preview - ulpravda.ru
Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 2,840 Shares - Defense World
Behavioral Patterns of RAPP and Institutional Flows - Stock Traders Daily
Krishnaswamy Yeleswaram Sells 2,840 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $197,338.35 in Stock - MarketBeat
Is Rapport Therapeutics Inc a good long term investmentSupport Level Holds & Free Discover Fast Growing Stocks - earlytimes.in
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 7.2%Here's What Happened - MarketBeat
Rapport Therapeutics, Inc. (RAPP): Investor Outlook with a 72% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
Guidance Update: Will Rapport Therapeutics Inc stock continue dividend increasesBull Run & AI Optimized Trade Strategies - moha.gov.vn
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Liquidity Mapping Around (RAPP) Price Events - Stock Traders Daily
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? - AOL.com
Rapport Therapeutics, Inc.(NasdaqGM:RAPP) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
How sustainable is Rapport Therapeutics Inc. stock dividend payoutWeekly Trade Review & Proven Capital Preservation Tips - Улправда
Rapport Therapeutics stock holds Buy rating at Goldman Sachs on epilepsy drug efficacy - Investing.com Canada
Rapport Therapeutics (NASDAQ:RAPP) CEO Sells $172,890.12 in Stock - MarketBeat
Rapport Therapeutics CEO Sells Shares Worth Over $323K - TradingView — Track All Markets
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Insider Sell: David Bredt Sells 8,500 Shares of Rapport Therapeu - GuruFocus
Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $255,170.00 in Stock - MarketBeat
Rapport Therapeutics CSO Sells Shares Under Trading Plan - TradingView — Track All Markets
Rapport Therapeutics Earnings Notes - Trefis
Assessing Rapport Therapeutics (RAPP) Valuation After Positive RAP-219 Phase 2a Epilepsy Data and Phase 3 Plans - Sahm
Price-Driven Insight from (RAPP) for Rule-Based Strategy - Stock Traders Daily
Wall Street Zen Upgrades Rapport Therapeutics (NASDAQ:RAPP) to Hold - MarketBeat
4.73%
0.92%
자본화:
|
볼륨(24시간):